Regular Article
Prognostic Factors of Primary Adenocarcinoma of the Uterine Cervix

https://doi.org/10.1006/gyno.1998.4971Get rights and content

Abstract

Objective.To determine which clinicopathological factors influence the prognosis of cervical adenocarcinoma.

Methods.Three hundred and two cases of primary adenocarcinoma of the uterine cervix, treated between 1977 and 1994, were studied retrospectively. Clinical data and pathological findings with respect to primary therapy were reviewed and evaluated.

Results.The 5-year survival rates for stages I, II, and III/IV were 75.9, 62.9, and 25.1%, respectively. International Federation of Gynecology and Obstetrics stage (P< 0.0001), cell type (P= 0.0176), tumor grade (P= 0.023), lymph node status (P= 0.018), and bulky tumor (P= 0.007) were found to be independent factors using the stepwise Cox proportional hazards model. Old age (P= 0.0581), presence of hypertension (P= 0.46), diabetes mellitus (P= 0.18), obesity (P= 0.15), and oral contraceptive use (P= 0.42) were not found to adversely influence survival rates for cervical adenocarcinoma after adjusting for other covariates. Adenosquamous adenocarcinoma had a better prognosis than endocervical columnar cell adenocarcinoma in stages I and II (P= 0.0235). Also, in cervical adenocarcinoma's early stages, multivariate modeling revealed that chances of survival were significantly better for patients treated by radical surgery than for patients treated by radiation therapy (P< 0.001).

Conclusions.Survival rates for cervical adenocarcinoma were significantly influenced by stage, histologic subtype, tumor grade, the presence of a positive lymph node, and tumor size. Although a randomized prospective study is needed, our data imply that radical surgery may be considered a better primary modality of treatment than radiation therapy for the early stages of cervical adenocarcinoma. Further, the presence of hypertension, diabetes mellitus, or obesity may not adversely influence survival rates.

References (37)

  • JR Van Nagell et al.

    Clinical correlates of endometrial carcinoma

    Am J Obstet Gynecol

    (1972)
  • G Ursin et al.

    Oral contraceptive use and adenocarcinoma of cervix

    Lancet

    (1994)
  • DM Parkin et al.

    Estimates of the worldwide incidence of eighteen major cancers in 1985

    Int J Cancer

    (1993)
  • B Piura et al.

    Adenocarcinoma of the uterine cervix: A study of 37 cases

    J Surg Oncol

    (1996)
  • RG Jorgensen et al.

    Early detection of vascular dysfunction in type I diabetes

    Diabetes

    (1988)
  • AP Soisson et al.

    Radical hysterectomy in obese women

    Obstet Gynecol

    (1992)
  • E Serur et al.

    Age, substance abuse, and survival of patients with cervical carcinoma

    Cancer

    (1995)
  • MI Wilde et al.

    Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations

    Drugs

    (1995)
  • Cited by (71)

    • Invasive cervical cancer

      2023, DiSaia and Creasman Clinical Gynecologic Oncology
    • Focus on mucinous adenocarcinoma of the uterine cervix

      2019, Gynecologie Obstetrique Fertilite et Senologie
    • Invasive cervical cancer

      2018, Clinical Gynecologic Oncology
    • Comparison of adenocarcinoma and adenosquamous carcinoma in patients with early-stage cervical cancer after radical surgery

      2014, Gynecologic Oncology
      Citation Excerpt :

      When patients were stratified into three risk groups according to the criteria of GOG protocols 92 and 109, histologic type (AdCa vs AdSCCa) had no clinical impact on RFS and OS in any of the risk groups. Because the incidence of AdCa and AdSCCa is increasing and most patients are diagnosed at an early stage, making them amenable to radical hysterectomy [5,8,17,25,26], it is important to establish the optimal management strategy and identify prognostic factors. We found that 5- and 10-year RFS rates were 88% and 85%, respectively, and 5- and 10-year OS rates were 92% and 88%, respectively, suggesting that our treatment strategy, consisting of radical hysterectomy followed by tailored adjuvant therapy, is appropriate for patients with these histologic varieties.

    • Invasive Cervical Cancer

      2012, Clinical Gynecologic Oncology: Eighth Edition
    • Invasive Cervical Cancer

      2007, Clinical Gynecologic Oncology
    View all citing articles on Scopus
    View full text